BioCentury
ARTICLE | Company News

Homology responds to reproducibility concerns

July 26, 2019 5:12 AM UTC

Homology is pushing back against a USC preprint study calling the reproducibility of the company’s cut-free gene editing platform into question. The study, which the company says stands in contrast to years of data supporting the technology, prompted investors to drive down the stock 20% on Thursday.

The new study, published Sunday on the preprint server bioRxiv, found that clade F adeno-associated viral (AAV) vectors -- the basis of the preclinical gene editing platform of Homology Medicine Inc. (NASDAQ:FIXX) -- were unable to efficiently make non-nuclease mediated homologous recombination edits...